Highly bioactive, bevacizumab-loaded, sustained-release PLGA/PCADK microspheres for intravitreal therapy in ocular diseases
Open Access
- 1 May 2019
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 563, 228-236
Abstract
No abstract availableKeywords
Funding Information
- Jilin Province Science and Technology Development Program (20180101269JC)
- State Key Laboratory of Long-acting and Targeting Drug Delivery System
- Shandong Luye Pharmaceutical Co., Ltd
This publication has 27 references indexed in Scilit:
- Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United StatesAmerican Journal of Ophthalmology, 2017
- Electrospun formulations of bevacizumab for sustained release in the eyeActa Biomaterialia, 2017
- Sequential delivery of chlorhexidine acetate and bFGF from PLGA-glycol chitosan core-shell microspheresColloids and Surfaces B: Biointerfaces, 2017
- PLGA nanoparticles from nano-emulsion templating as imaging agents: Versatile technology to obtain nanoparticles loaded with fluorescent dyesColloids and Surfaces B: Biointerfaces, 2016
- Microspheres prepared with different co-polymers of poly(lactic-glycolic acid) (PLGA) or with chitosan cause distinct effects on macrophagesColloids and Surfaces B: Biointerfaces, 2015
- The genetics of age-related macular degeneration (AMD) – Novel targets for designing treatment options?European Journal of Pharmaceutics and Biopharmaceutics, 2015
- Protein stability in the presence of polymer degradation products: Consequences for controlled release formulationsBiomaterials, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- BevacizumabNature Reviews Drug Discovery, 2005
- Effect of Moisture on the Stability of a Lyophilized Humanized Monoclonal Antibody FormulationPharmaceutical Research, 2001